

ANNUAL CANCER REGISTRY REPORT-2019, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN

Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Ain ul Quader, Hina Asif, Adna Atif, Lubna Nadeem, Natasha Parveen, Roma Tanveer, Azam Hussain, Ayesha Zafar and Farhana Badar.

CANCER STATISTICS

This report includes patients registered at the centers affiliated with the Shaukat Khanum Memorial Trust and accessioned into the hospital information system in Lahore. The affiliated centers include two hospitals called the 'Shaukat Khanum Memorial Cancer Hospital and Research Center' (SKMCH&RC) in Lahore and Peshawar and the Karachi Diagnostic Center (KDC). SKMCH&RC Lahore is the oldest center and has been functioning since December 29, 1994, SKMCH&RC Peshawar since December 29, 2015, KDC since 2010 and SKDCL in August 01, 2019. For the purpose of presenting the results, all of these centers are referred to as SKMCH&RC/hospital in this report.

Distribution of neoplasms

Of a total of 7,044 new neoplasms diagnosed or treated at the aforementioned facilities in Pakistan, from January 1, 2019 to December 31, 2019, 3,253 were seen in male (46.2%) and 3791 (53.8%) in female patients. Six thousand, five hundred and eleven (6511 (92.4%)) neoplasms were found in adults, whereas, 533 (7.6%) were seen in children. Children were classified as those 18-years or less and adults as more than 18-years of age. Table 1 shows the stratification of cases by behavior and age-group.

Table 1. Distribution of neoplasms by behavior and age-group, from Jan. 2019 to Dec. 2019.

| Behavior | Age-group | Registered patients (6,764) | Reported neoplasm* (7,044) |
|--|------------------|--|---------------------------------------|
| Malignant[†] | Adults | 5,848 | 5,928 |
| | Pediatrics | 517 | 518 |
| | Total | 6,365 | 6,446 |
| Benign[‡] & Uncertain Behavior | Adults | 524 | 583 |
| | Pediatrics | 14 | 15 |
| | Total | 538 | 598 |

* The difference in the number of registered patients and reported neoplasms is attributed to multiple malignancies and benign neoplasms diagnosed in 81 and 60 patients, respectively. Further, 139 patients have both malignant and benign neoplasm simultaneously.

[†] Cases with behavior code /3 and /2 are considered as malignant cases.


[‡] Cases with behavior code /0 and /1 are considered as benign and uncertain, respectively.

[§] According to the Facility Oncology Revised Data Standards (FORDS), Revised for 2004, Class of Case 0 to 2 are analytical cases and included in treatment and survival analysis, whereas, Class of Case 3 to 9 are non-analytical cases, usually not included in routine treatment or survival statistics.

Class of Case

Of a total of 6,446 malignant cases recorded in the Registry from January 2019 to December 2019, 6291 (97.6%) were analytical cases and 155 (2.4%) non-analytical. Figure 1 shows the stratification of analytical and non-analytical cases[¥].

Figure 1. Stratification of analytical and non-analytical cases, from Jan. 2019 to Dec. 2019.




Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

Distribution of malignancies

In the year 2019, a total of 6,446 malignancies were diagnosed at the hospital with 3,323 seen amongst females and 3,123 amongst males. Table 2 displays the distributions of female and male patients according to sex and age-group.

Table 2 and figure 2. Distribution of cancer cases by sex and age-group (yrs.), from Jan. 2019 to Dec. 2019.

| Age-range | Female | Male | Total |
|--------------|-------------|-------------|-------------|
| 0-4 | 86 | 157 | 243 |
| 5-9 | 26 | 99 | 125 |
| 10-14 | 27 | 35 | 62 |
| 15-19 | 59 | 95 | 154 |
| 20-24 | 111 | 174 | 285 |
| 25-29 | 164 | 194 | 358 |
| 30-34 | 329 | 266 | 595 |
| 35-39 | 443 | 281 | 724 |
| 40-44 | 448 | 253 | 701 |
| 45-49 | 414 | 251 | 665 |
| 50-54 | 330 | 253 | 583 |
| 55-59 | 290 | 234 | 524 |
| 60-64 | 250 | 285 | 535 |
| 65-69 | 161 | 280 | 441 |
| 70-74 | 109 | 149 | 258 |
| 75-79 | 43 | 72 | 115 |
| 80-84 | 23 | 36 | 59 |
| 85+ | 10 | 9 | 19 |
| Total | 3323 | 3123 | 6446 |




Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

Demographics

Of the 6,446 malignant cancers, nearly 57.7% (3,720) belonged to the province of Punjab and approximately 24.7% (1,595) to Khyber Pakhtunkhwa (Table 3). The fact that the geographic area of residence of a vast majority of patients was Punjab can be explained in light of the information that the oldest affiliate is situated in the provincial capital of Punjab and that, this province accounts for almost 50% of the total population of the country.

Table 3. Distribution of malignancies according to the geographic area of residence of the patients, from Jan. 2019 to Dec. 2019.

| Province/Region | Malignancies | Percentage |
|----------------------------------|--------------|--------------|
| Punjab | 3,720 | 57.7 |
| Khyber Pakhtunkhwa & F.A.T.A [1] | 1,595 | 24.7 |
| Sindh | 177 | 2.8 |
| Balochistan | 81 | 1.3 |
| Federal Capital | 71 | 1.1 |
| Gilgit-Baltistan | 9 | 0.1 |
| Azad Jammu & Kashmir | 65 | 1.0 |
| Afghanistan | 726 | 11.3 |
| Other countries | 2 | 0.03 |
| Total | 6,446 | 100.0 |



Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

^[1] Khyber Pakhtunkhwa and F.A.T.A merged on May 28, 2018.


Top ten cancers

Tables 4 to 8 show the list of the ten commonest malignancies seen at SKMCH&RC during the year 2019. Of a total of 6,446 malignancies, breast cancer was the leading malignancy with 1,479 cases accessioned into the Registry. Cancers of the colon/rectum/anal canal/anus, and lip & oral cavity were the second and third most frequently seen cancers, respectively.

Table 4. Top 10 malignancies seen amongst all age-groups, both sexes combined, from Jan. 2019 to Dec. 2019.

| Sr. No. | ICD-O-3 Category | Count | Percentage | ICD-O-3 Code |
|---------|------------------------------|-------|------------|------------------------|
| 1 | Breast | 1,479 | 22.9 | C50.0 - C50.9 |
| 2 | Colon/rectum/anal canal/anus | 486 | 7.5 | C18.0 - C21.8 |
| 3 | Lip and oral cavity | 348 | 5.4 | C00.0 - C08.9 |
| 4 | Non-Hodgkin lymphoma | 321 | 5.0 | M9590 - 91, M967 - 972 |
| 5 | Prostate | 230 | 3.6 | C61.9 |
| 6 | Brain | 228 | 3.5 | C71.0 - C71.9 |
| 7 | Skin | 218 | 3.4 | C44 |
| 8 | Hodgkin lymphoma | 216 | 3.4 | M9650 - M9667 |
| 9 | Leukemia | 198 | 3.1 | M9800 - M9948 |
| 10 | Trachea, bronchus & lung | 189 | 2.9 | C33.9 - C34.9 |

Figure 3. Top 10 malignancies seen amongst all age-groups, both sexes combined, from Jan. 2019 to Dec. 2019.




Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

Amongst adults, during the year 2019, a total of 5,928 malignancies were diagnosed or treated at SKMCH&RC. Cancers of the breast, colon/rectum/anal canal/anus, and lip and oral cavity were registered as the most frequently seen cancers.

Table 5. Top 10 malignancies seen amongst adults (> 18 years), from Jan. 2019 to Dec. 2019.

| Sr. No. | ICD-O-3 Category | Count | Percentage | ICD-O-3 Code |
|---------|------------------------------|-------|------------|------------------------|
| 1 | Breast | 1479 | 24.9 | C50.0 - C50.9 |
| 2 | Colon/rectum/anal canal/anus | 484 | 8.2 | C18.0 - C21.8 |
| 3 | Lip and oral cavity | 347 | 5.9 | C00.0 - C08.9 |
| 4 | Non-Hodgkin lymphoma | 252 | 4.3 | M9590 - 91, M967 - 972 |
| 5 | Prostate | 230 | 3.9 | C61.9 |
| 6 | Brain | 222 | 3.7 | C71.0 - C71.9 |
| 7 | Skin | 217 | 3.7 | C44.0 - C44.9 |
| 8 | Trachea, bronchus & lung | 188 | 3.2 | C33.9 - C34.9 |
| 9 | Thyroid | 183 | 3.1 | C73.9 |
| 10 | Esophagus | 173 | 2.9 | C15 |

Figure 4. Top 10 malignancies seen amongst adults (> 18 years), from Jan. 2019 to Dec. 2019.




Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

In 518 childhood malignancies, using the classification based on tumor morphology, acute lymphoblastic leukemia, non-Hodgkin lymphoma, and retinoblastoma were identified as the three most common malignancies diagnosed or treated at SKMCH&RC. Table 6 shows the distributions of the top ten malignancies seen in children at SKMCH&RC.

Table 6. Top 10 malignancies seen in children (<= 18 years), from Jan. 2019 to Dec. 2019.

| Sr. No. | ICD-O-3 Category | Count | Percentage | ICD-O-3 Morphology Code |
|---------|------------------------------|-------|------------|-------------------------|
| 1 | Acute lymphoblastic leukemia | 108 | 20.8 | M982 - M983 |
| 2 | Non-Hodgkin lymphoma | 68 | 13.1 | M9590 - 91, M967 - 972 |
| 3 | Retinoblastoma | 67 | 12.9 | M9510 - M9514 |
| 4 | Hodgkin lymphoma | 65 | 12.5 | M9650 - M9667 |
| 5 | Osteosarcoma | 63 | 12.2 | M9180 - M9195 |
| 6 | Ewing's sarcoma/PNET | 47 | 9.1 | M9260 |
| 7 | Germ cell tumor | 23 | 4.4 | M906 - M909 |
| 8 | Nephroblastoma | 20 | 3.9 | M8960 |
| 9 | Rhabdomyosarcoma | 8 | 1.5 | M8900 - M8921 |
| 10 | Hepatoblastoma | 7 | 1.4 | M8970 |

Figure 5. Top 10 malignancies seen in children (<= 18 years), from Jan. 2019 to Dec. 2019.




Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

In adult males (2,785 malignancies), the commonest cancers were those of the colon/rectum/anal canal/anus, prostate, and lip & oral cavity (Table 7).

Table 7. Top 10 malignancies seen amongst adult males, from Jan. 2019 to Dec. 2019.

| Sr.No. | ICD Category | Count | Percentage | ICD-O-3 Code |
|--------|--------------------------------|-------|------------|------------------------|
| 1 | Colon/rectum/anal canal/anus | 333 | 12.0 | C18 - C21.8 |
| 2 | Prostate | 230 | 8.3 | C61.9 |
| 3 | Lip and oral cavity | 207 | 7.4 | C00.0 - C08.9 |
| 4 | Non-Hodgkin lymphoma | 178 | 6.4 | M9590 - 91, M967 - 972 |
| 5 | Brain | 155 | 5.6 | C71 |
| 6 | Trachea, bronchus & lung | 149 | 5.3 | C33.9 - C34.9 |
| 7 | Testis | 144 | 5.2 | C62 |
| 8 | Skin | 124 | 4.5 | C44 |
| 9 | Bladder | 100 | 3.6 | C67 |
| 10 | Liver & intrahepatic bile duct | 100 | 3.6 | C22 |

Figure 6. Top 10 malignancies seen amongst adult males, from Jan. 2019 to Dec. 2019.




Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

The most frequent diagnosis in adult women (3,150) was breast cancer accounting for 46.7% of the cancers. Cervix uteri was ranked as the second highest cancer (5.0%) and cancers of the colon, rectum, anal canal and anus as the third common malignancy with 4.8% of the total malignancies, in females.

Table 8. Top 10 malignancies seen amongst adult females, from Jan. 2019 to Dec. 2019.

| Sr. No. | ICD Category | Count | Percentage | ICD-O 3 Code |
|---------|------------------------------|-------|------------|------------------------|
| 1 | Female breast | 1,471 | 46.7 | C50.0 - C50.9 |
| 2 | Cervix uteri | 157 | 5.0 | C53.0 - C53.9 |
| 3 | Colon/rectum/anal canal/anus | 152 | 4.8 | C18 - C21.8 |
| 4 | Lip and oral cavity | 140 | 4.4 | C00.0 - C08.9 |
| 5 | Thyroid | 117 | 3.7 | C73.9 |
| 6 | Corpus uteri and uterus | 109 | 3.5 | C54.0 - C55.9 |
| 7 | Esophagus | 99 | 3.1 | C15 - C15.9 |
| 8 | Skin | 93 | 3.0 | C44.0 - C44.9 |
| 9 | Non-Hodgkin lymphoma | 76 | 2.4 | M9590 - 91, M967 - 972 |
| 10 | Brain | 67 | 2.1 | C71.0 - C71.9 |

Figure 7. Top 10 malignancies seen amongst adult females, from Jan. 2019 to Dec. 2019.



Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC


Staging

The Registry uses the American Joint Commission on Cancer TNM staging system for all analytical cancer cases. TNM categorizes cancers in stages 0, 1, 2, 3, 4, unstageable, and not applicable on all analytical cases (Class of Case 0, 1, 2). Cancers are classified as being unstageable as the patients may choose not to receive any treatment or undergo further tests at the hospital needed to establish an appropriate stage. “Not applicable” means non-availability of AJCC staging for that site. During the year 2019, cancer staging for 6,291 analytical cases (Class of Case 0, 1, 2) showed that 45 (0.7%) cases fell into 0 or in situ category, 955 (15.2%) in Stage I, 1,716 (27.3%) in Stage II, 1,367 (21.7%) cases in Stage III, and 1152 (18.3%) in Stage IV, (table 9); 517 (8.2%) cases were unstageable and 539 (8.6%) had no AJCC stage defined for that site.

Table 9. TNM Stage of cancer patients at SKMCH&RC, from Jan. 2019 to Dec. 2019.

| AJCC Stage | Count | Percentage |
|------------------------|--------------|-------------------|
| Stage 0 | 45 | 0.7 |
| Stage I | 955 | 15.2 |
| Stage II | 1,716 | 27.3 |
| Stage III | 1,367 | 21.7 |
| Stage IV | 1,152 | 18.3 |
| Unstageable | 517 | 8.2 |
| AJCC stage not defined | 539 | 8.6 |
| Total | 6,291 | 100.0 |

Figure 8. TNM stage of cancer patients at SKMCH&RC, from Jan. 2019 to Dec. 2019.



Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC


Summary Stage

The SEER Summary Staging Manual-2000 Codes and Coding Instructions were used to describe how far the tumor had spread from the organ or the site of origin. This manual consists of a one-digit hierarchical code for each and every site. All analytical cases (Class of Case 0, 1, 2), were included to generate results. The cancer data for the year 2019 reflects that there were 0.7% in situ cases, 24.3% localized cancers, 41.6% regional cases, 19.1% distant, and there were 14.3% cases in which the summary stage was unknown.

Table 10. Classification of patients according to the SEER summary stage, from Jan. 2019 to Dec. 2019.

| SEER Summary Stage | Count | Percentage |
|---------------------------|--------------|-------------------|
| In situ | 41 | 0.7 |
| Local | 1,528 | 24.3 |
| Regional | 2,618 | 41.6 |
| Distant | 1,200 | 19.1 |
| Unknown | 904 | 14.3 |
| Total | 6,291 | 100.0 |

Figure 9. Classification according to the SEER Summary Stage, from Jan. 2019 to Dec. 2019.



Data Source: Cancer Registry & Clinical Data Management, SKMCH&RC

Grade/Differentiation/Immunophenotype

The International Classification of Diseases for Oncology, Third Edition (ICD-O-3), codes and guidelines have been used to categorize grade/differentiation/immunophenotype. All analytical cases (Class of Case 0, 1, 2), were included to generate results.

Table 11. Grade/differentiation/immunophenotype of cancers from Jan. 2019 to Dec. 2019.

| Grade/Differentiation/Immunophenotype | Count | Percentage |
|---|--------------|-------------------|
| Grade I | 471 | 7.5 |
| Grade II | 1,986 | 31.6 |
| Grade III | 1,379 | 21.9 |
| Grade IV | 131 | 2.1 |
| T-cell | 23 | 0.4 |
| B-cell | 359 | 5.7 |
| Nk Cell (Natural Killer Cell) | 1 | 0.01 |
| Grade/differentiation/immunophenotype not determined, not stated, or not applicable | 1,941 | 30.9 |
| Total | 6,291 | 100.0 |

SUPPLEMENTAL INFORMATION

Table 12 depicts the results stratified by primary site, age-group, and gender. According to this, cancers of the breast, colon/rectum/anal canal/anus, lymphoma and lip and oral cavity and skin are the commonest systems/site(s) for malignancies seen at SKMCH&RC. Table 13 shows the results stratified by gender, primary site, and morphology.

Table 12. Distribution by gender, primary malignant site, and 5-year age-group, 2019

FEMALES

| ICD-O-3 Code* | Primary Site | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ | Total |
|-------------------|---|-----------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|-----------|-----------|-------------|
| C00 | Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| C01-C02 | Tongue | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 4 | 11 | 8 | 6 | 9 | 4 | 7 | 0 | 0 | 1 | 56 |
| C03 | Gum | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 12 |
| C04-C06 | Floor and other parts of mouth | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 6 | 3 | 6 | 6 | 6 | 5 | 2 | 1 | 2 | 47 |
| C07-C08 | Salivary gland | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 21 |
| C09-C10 | Tonsil & oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C11 | Nasopharynx | 0 | 0 | 0 | 0 | 4 | 1 | 2 | 3 | 1 | 2 | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 20 |
| C12-C13 | Pyiform sinus & Hypopharynx | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 5 | 1 | 3 | 3 | 3 | 1 | 2 | 1 | 0 | 0 | 0 | 24 |
| C14 | Other & ill-defined lip, oral cavity, pharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C15 | Esophagus | 0 | 0 | 0 | 0 | 1 | 6 | 13 | 20 | 40 | 8 | 5 | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 99 |
| C16 | Stomach | 0 | 0 | 0 | 1 | 1 | 2 | 8 | 14 | 6 | 1 | 2 | 2 | 7 | 2 | 0 | 1 | 0 | 0 | 47 |
| C17 | Small intestine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 10 |
| C18 | Colon | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 5 | 5 | 9 | 2 | 7 | 4 | 4 | 4 | 5 | 0 | 0 | 50 |
| C19-C21 | Rectosigmoid, rectum, anal canal, and anus | 0 | 0 | 0 | 2 | 7 | 10 | 15 | 7 | 11 | 8 | 7 | 12 | 10 | 5 | 6 | 3 | 0 | 0 | 103 |
| C22 | Liver & intrahepatic bile duct | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 2 | 7 | 8 | 3 | 2 | 2 | 3 | 0 | 35 |
| C23-C24 | Gall bladder & extrahepatic bile duct | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 10 | 6 | 6 | 6 | 6 | 4 | 0 | 1 | 0 | 44 |
| C25 | Pancreas | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 5 | 1 | 2 | 1 | 0 | 30 |
| C30-C31 | Nasal cavity, middle ear and acc. sinuses | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 1 | 1 | 0 | 0 | 0 | 11 |
| C32 | Larynx | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 8 |
| C33-C34 | Trachea, bronchus & lung | 0 | 0 | 0 | 1 | 0 | 4 | 3 | 5 | 1 | 1 | 3 | 5 | 5 | 6 | 2 | 2 | 2 | 0 | 40 |
| C37-C38 | Thymus, heart, mediastinum & pleura | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C40-C41 | Bone & articular cartilage | 3 | 7 | 18 | 16 | 1 | 2 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 53 |
| C44 | Skin | 0 | 0 | 0 | 2 | 1 | 2 | 4 | 6 | 8 | 14 | 10 | 10 | 10 | 8 | 9 | 4 | 4 | 2 | 94 |
| C47 | Peripheral & autoimmune nervous system | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C48 | Peritoneum & Retroperitoneum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| C49 | Connective & soft tissue | 0 | 2 | 3 | 4 | 6 | 8 | 8 | 5 | 7 | 3 | 5 | 5 | 2 | 5 | 1 | 2 | 1 | 0 | 67 |
| C50 | Breast | 0 | 0 | 0 | 0 | 15 | 58 | 180 | 260 | 248 | 235 | 156 | 125 | 89 | 56 | 30 | 12 | 4 | 3 | 1471 |
| C51-C52 | Vulva & vagina | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 5 |
| C53 | Cervix uteri | 0 | 0 | 0 | 1 | 3 | 5 | 3 | 14 | 35 | 23 | 32 | 18 | 18 | 4 | 0 | 1 | 0 | 1 | 158 |
| C54 | Corpus uteri | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 8 | 8 | 8 | 17 | 12 | 20 | 8 | 9 | 1 | 2 | 0 | 101 |
| C55 | Uterus | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 8 |
| C56-C57 | Ovary & other female genital organs | 0 | 1 | 3 | 3 | 3 | 2 | 2 | 6 | 8 | 7 | 10 | 6 | 7 | 4 | 4 | 0 | 1 | 0 | 67 |
| C64-C66 | Kidney & other urinary organ | 7 | 2 | 0 | 0 | 0 | 2 | 7 | 3 | 3 | 9 | 13 | 8 | 11 | 2 | 2 | 0 | 0 | 0 | 69 |
| C67 | Urinary bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 4 | 2 | 1 | 1 | 3 | 4 | 1 | 1 | 0 | 21 |
| C69 | Eye | 26 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 |
| C70-C71 | Brain | 0 | 0 | 0 | 2 | 6 | 8 | 13 | 17 | 10 | 5 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 67 |
| C72 | Other parts of nervous system | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| C73 | Thyroid gland | 0 | 0 | 0 | 5 | 7 | 17 | 22 | 16 | 17 | 14 | 7 | 6 | 3 | 3 | 0 | 0 | 0 | 0 | 117 |
| C74-C75 | Endocrine gland and related structure | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| C76 | Other and ill-defined sites | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| C80 | Unknown primary | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 5 | 1 | 4 | 5 | 1 | 0 | 0 | 20 |
| M9650-M9667 | Hodgkin lymphoma | 1 | 3 | 0 | 5 | 22 | 11 | 9 | 8 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 63 |
| M9590-91, 967-972 | Non-Hodgkin lymphoma | 8 | 5 | 0 | 4 | 11 | 5 | 3 | 14 | 9 | 3 | 4 | 7 | 5 | 6 | 4 | 3 | 1 | 0 | 92 |
| M9731-M9732 | Multiple myeloma & immuno. neoplasms | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
| M982-M983 | Lymphoid leukemia | 35 | 2 | 0 | 3 | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 47 |
| M984-M993 | Myeloid leukemia | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 1 | 0 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 12 |
| M994 | Other leukemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| C42.0, C42.2-4 | Other lymphatic & hematopoietic tissue | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 6 |
| ~ | Other reportable CNS neoplasms | 0 | 0 | 0 | 4 | 7 | 4 | 14 | 7 | 3 | 6 | 5 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 56 |
| | Total | 86 | 26 | 27 | 59 | 111 | 164 | 329 | 443 | 448 | 414 | 330 | 290 | 250 | 161 | 109 | 43 | 23 | 10 | 3323 |

MALES

| ICD-O-3 Code | Primary Site | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ | Total |
|------------------|--|------------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|-----------|----------|-------------|
| C00 | Lip | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 16 |
| C01-C02 | Tongue | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 10 | 8 | 5 | 14 | 9 | 8 | 12 | 2 | 1 | 0 | 0 | 77 |
| C03 | Gum | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 3 | 3 | 0 | 7 | 2 | 3 | 0 | 0 | 0 | 25 |
| C04-C06 | Floor and other parts of mouth | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 6 | 6 | 10 | 9 | 7 | 4 | 5 | 3 | 1 | 0 | 0 | 56 |
| C07-C08 | Salivary gland | 0 | 0 | 0 | 0 | 2 | 5 | 7 | 0 | 5 | 7 | 0 | 2 | 1 | 1 | 0 | 3 | 0 | 0 | 33 |
| C9-C10 | Tonsil & oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 5 |
| C11 | Nasopharynx | 0 | 0 | 0 | 3 | 4 | 2 | 8 | 16 | 5 | 6 | 10 | 9 | 4 | 7 | 3 | 1 | 1 | 0 | 79 |
| C12-C13 | Pyiform sinus & Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 3 | 0 | 3 | 4 | 1 | 2 | 0 | 0 | 18 |
| C15 | Esophagus | 0 | 0 | 0 | 0 | 3 | 2 | 8 | 11 | 26 | 6 | 2 | 5 | 1 | 4 | 4 | 1 | 1 | 0 | 74 |
| C16 | Stomach | 0 | 0 | 0 | 0 | 3 | 4 | 6 | 18 | 20 | 11 | 7 | 4 | 6 | 2 | 4 | 2 | 0 | 0 | 87 |
| C17 | Small intestine | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 1 | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 15 |
| C18 | Colon | 0 | 0 | 0 | 0 | 3 | 7 | 11 | 12 | 16 | 22 | 14 | 16 | 17 | 9 | 5 | 5 | 2 | 0 | 139 |
| C19-C21 | Rectosigmoid, rectum, anal canal, and anus | 0 | 0 | 0 | 2 | 15 | 15 | 25 | 28 | 22 | 15 | 17 | 19 | 10 | 16 | 7 | 1 | 2 | 0 | 194 |
| C22 | Liver & intrahepatic bile duct | 6 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 5 | 17 | 12 | 16 | 16 | 17 | 8 | 1 | 0 | 1 | 106 |
| C23-C24 | Gall Bladder & extrahepatic bile duct | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 5 | 10 | 8 | 10 | 7 | 3 | 2 | 0 | 1 | 56 |
| C25 | Pancreas | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 2 | 5 | 9 | 6 | 8 | 18 | 12 | 4 | 3 | 0 | 0 | 71 |
| C30-C31 | Nasal cavity, middle ear and acc. sinuses | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 0 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 14 |
| C32 | Larynx | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 4 | 3 | 5 | 15 | 12 | 17 | 14 | 9 | 2 | 2 | 1 | 88 |
| C33-C34 | Bronchus & Lung | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 5 | 11 | 18 | 18 | 24 | 29 | 22 | 10 | 5 | 0 | 149 |
| C37-C38 | Thymus, heart, mediastinum & pleura | 0 | 0 | 0 | 0 | 1 | 3 | 5 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 14 |
| C40-C41 | Bone & articular cartilage | 6 | 6 | 29 | 26 | 5 | 5 | 2 | 2 | 2 | 1 | 2 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 92 |
| C44 | Skin | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 5 | 6 | 8 | 19 | 15 | 22 | 19 | 8 | 2 | 8 | 2 | 124 |
| C47 | Peripheral. & autoimmune nervous system | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C48 | Retroperitoneum and Peritoneum | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C49 | Connective & soft tissue | 3 | 4 | 1 | 4 | 9 | 7 | 7 | 10 | 3 | 8 | 4 | 6 | 4 | 3 | 2 | 1 | 3 | 0 | 79 |
| C50 | Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 8 |
| C60 | Penis | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C61 | Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 17 | 26 | 58 | 74 | 27 | 16 | 6 | 2 | 230 |
| C62 | Testis | 8 | 0 | 0 | 12 | 28 | 36 | 32 | 15 | 15 | 6 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 156 |
| C63 | Other & unspecified male genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C64-C66 | Kidney & other urinary organ | 11 | 1 | 0 | 2 | 1 | 1 | 5 | 7 | 15 | 14 | 13 | 11 | 11 | 4 | 5 | 3 | 0 | 0 | 104 |
| C67 | Urinary bladder | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 8 | 11 | 22 | 12 | 9 | 5 | 10 | 6 | 6 | 2 | 2 | 100 |
| C68 | Other and unspecified urinary organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C69 | Eye | 31 | 6 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 39 |
| C70-C71 | Brain | 0 | 2 | 1 | 3 | 17 | 27 | 34 | 25 | 20 | 11 | 6 | 1 | 4 | 5 | 4 | 1 | 0 | 0 | 161 |
| C72 | Other parts of nervous system | 0 | 0 | 1 | 2 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| C73 | Thyroid gland | 0 | 0 | 0 | 0 | 9 | 6 | 10 | 12 | 8 | 3 | 7 | 4 | 4 | 1 | 0 | 1 | 1 | 0 | 66 |
| C74-C75 | Endocrine gland and related structure | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 8 |
| C76 | Other and ill-defined sites | 1 | 0 | 0 | 2 | 2 | 3 | 2 | 0 | 1 | 4 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 17 |
| C80 | Unknown primary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 5 | 4 | 5 | 1 | 3 | 0 | 1 | 0 | 21 |
| M9650-M9667 | Hodgkin lymphoma | 15 | 40 | 2 | 11 | 22 | 21 | 20 | 6 | 7 | 7 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 153 |
| M9590-91,967-972 | Non-Hodgkin lymphoma | 18 | 31 | 0 | 8 | 17 | 19 | 36 | 36 | 16 | 12 | 9 | 5 | 9 | 5 | 6 | 1 | 1 | 0 | 229 |
| M9731-M9732 | Multiple myeloma & immuno. neoplasms | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 7 |
| M982-M983 | Lymphoid leukemia | 57 | 8 | 1 | 12 | 18 | 4 | 0 | 0 | 3 | 2 | 3 | 3 | 2 | 3 | 0 | 3 | 0 | 0 | 119 |
| M984-M993 | Myeloid leukemia | 0 | 0 | 0 | 3 | 3 | 1 | 1 | 3 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 16 |
| M994 | Other leukemia | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| C42.0, C42.2-4 | Other lymphatic & hematopoietic tissue | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 7 |
| ~ | Other reportable CNS neoplasms | 0 | 0 | 3 | 3 | 2 | 11 | 11 | 3 | 8 | 1 | 3 | 2 | 4 | 2 | 1 | 0 | 0 | 55 | 1 |
| | Total | 157 | 99 | 35 | 95 | 174 | 194 | 266 | 281 | 253 | 251 | 253 | 234 | 285 | 280 | 149 | 72 | 36 | 9 | 3123 |

*Diseases are listed according to the International Classification of Diseases for Oncology, Third edition (ICD-O-3) codes.

~Non-malignant primary intracranial and CNS tumors are also included in the count.

Table 13 - Morphology, site, and gender, 2019

| ICD-O-3 Code | Morphology | Female | Male | Total |
|---|--|--------|------|-------|
| C00 Lip | Squamous Cell Carcinoma, Nos | | 7 | 7 |
| | Adenoid Cystic Carcinoma | | 2 | 2 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | | 1 | 1 |
| C01-02 Tongue | Squamous Cell Carcinoma, Nos | 44 | 70 | 114 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 3 | 2 | 5 |
| | Adenoid Cystic Carcinoma | 1 | | 1 |
| | Mucoepidermoid Carcinoma | 1 | | 1 |
| | Squamous Cell Carcinoma In Situ, Nos | | 1 | 1 |
| C03-06 Gum, FOM, palate, other & unspecified parts of mouth | Squamous Cell Carcinoma, Nos | 20 | 65 | 85 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 3 | 9 | 12 |
| | Mucoepidermoid Carcinoma | 2 | 5 | 7 |
| | Adenoid Cystic Carcinoma | 1 | 5 | 6 |
| | Carcinoma, Nos | 1 | 2 | 3 |
| | Adenocarcinoma, Nos | 1 | 1 | 2 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 2 | 2 |
| | Squamous Cell Carcinoma, Spindle Cell | 1 | | 1 |
| Verrucous Carcinoma, Nos | 1 | | 1 | |
| C07-08 Parotid and other major Salivary glands | Mucoepidermoid Carcinoma | 7 | 11 | 18 |
| | Carcinoma, Nos | 3 | 8 | 11 |
| | Adenoid Cystic Carcinoma | 7 | 2 | 9 |
| | Acinar Cell Carcinoma | 3 | 3 | 6 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 2 | 2 |
| | Squamous Cell Carcinoma, Nos | 1 | 1 | 2 |
| | Adenocarcinoma, Nos | | 1 | 1 |
| | Lymphoepithelial Carcinoma | | 1 | 1 |
| | Neoplasm, Malignant | | 1 | 1 |
| | Secretory Carcinoma Of Breast | | 1 | 1 |
| C09-C10 Tonsil & oropharynx | Malignant Lymphoma, Large B-Cell Diffuse Nos | 3 | 3 | 6 |
| | Squamous Cell Carcinoma, Nos | 1 | 4 | 5 |
| | Burkitt Lymphoma, Nos | | 3 | 3 |
| | Carcinoma, Nos | | 1 | 1 |
| | Cribriform Carcinoma, Nos | 1 | | 1 |
| C11 Nasopharynx | Carcinoma, Nos | 14 | 18 | 32 |

| | | | | |
|---|---|----|----|-----|
| | Carcinoma, Undifferentiated, Nos | 12 | 16 | 28 |
| | Squamous Cell Carcinoma, Nos | 1 | 3 | 4 |
| | Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, Nos | | 2 | 2 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Malignant Melanoma, Nos | 1 | | 1 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | | 1 | 1 |
| C12-C13 Pyriform sinus & Hypopharynx | Squamous Cell Carcinoma, Nos | 12 | 23 | 35 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 3 | 1 | 4 |
| | Basaloid Squamous Cell Carcinoma | | 1 | 1 |
| C14 Other & ill-defined sites in lip, oral cavity & pharynx | | | | |
| | Squamous Cell Carcinoma, Nos | | 2 | 2 |
| C15 Esophagus | Squamous Cell Carcinoma, Nos | 97 | 79 | 176 |
| | Adenocarcinoma, Nos | | 11 | 11 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 2 | 9 | 11 |
| | Carcinoma, Nos | 2 | 1 | 3 |
| | Neuroendocrine Carcinoma, Nos | 1 | | 1 |
| C16 Stomach | Adenocarcinoma, Nos | 20 | 57 | 77 |
| | Signet Ring Cell Carcinoma | 23 | 40 | 63 |
| | Gastrointestinal Stromal Sarcoma | 9 | 8 | 17 |
| | Squamous Cell Carcinoma, Nos | 6 | 6 | 12 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 1 | 6 | 7 |
| | Neuroendocrine Carcinoma, Nos | 3 | 1 | 4 |
| | Carcinoma, Nos | 1 | 2 | 3 |
| | Adenocarcinoma In Villous Adenoma | 1 | 1 | 2 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | | 2 | 2 |
| | Adenocarcinoma In Adenomatous Polyp | | 1 | 1 |
| | Adenocarcinoma In Tubulovillous Adenoma | | 1 | 1 |
| | Marginal Zone B-Cell Lymphoma, Nos | | 1 | 1 |
| | Mucinous Adenocarcinoma | | 1 | 1 |
| Pseudosarcomatous Carcinoma | | 1 | 1 | |
| C17 Small intestine | Gastrointestinal Stromal Sarcoma | 2 | 8 | 10 |
| | Adenocarcinoma, Nos | 2 | 6 | 8 |
| | Neuroendocrine Carcinoma, Nos | 1 | 4 | 5 |
| | Burkitt Lymphoma, Nos | 1 | 2 | 3 |

| | | | | |
|---|---|----|-----|-----|
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Mucinous Adenocarcinoma | 1 | | 1 |
| | Signet Ring Cell Carcinoma | | 1 | 1 |
| C18 Colon | Adenocarcinoma, Nos | 35 | 63 | 98 |
| | Mucinous Adenocarcinoma | 6 | 16 | 22 |
| | Signet Ring Cell Carcinoma | 2 | 6 | 8 |
| | Adenocarcinoma In Tubulovillous Adenoma | 3 | 4 | 7 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 2 | 3 | 5 |
| | Adenocarcinoma In Villous Adenoma | | 2 | 2 |
| | Adenocarcinoma In Adenomatous Polyp | 1 | | 1 |
| | Burkitt Lymphoma, Nos | 1 | | 1 |
| | Gastrointestinal Stromal Sarcoma | 1 | | 1 |
| | Neuroendocrine Carcinoma, Nos | | 1 | 1 |
| | Tubular Adenocarcinoma | | 1 | 1 |
| C19-C21 Rectosigmoid junction, rectum, anal canal, and anus | Adenocarcinoma, Nos | 54 | 120 | 174 |
| | Signet Ring Cell Carcinoma | 27 | 47 | 74 |
| | Adenocarcinoma In Tubulovillous Adenoma | 17 | 16 | 33 |
| | Mucinous Adenocarcinoma | 10 | 14 | 24 |
| | Neoplasm, Malignant | 1 | 2 | 3 |
| | Squamous Cell Carcinoma, Nos | | 3 | 3 |
| | Adenocarcinoma In Adenomatous Polyp | | 2 | 2 |
| | Adenocarcinoma In Villous Adenoma | 1 | 1 | 2 |
| | Carcinoma, Nos | 1 | 1 | 2 |
| | Neuroendocrine Carcinoma, Nos | | 2 | 2 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | | 2 | 2 |
| | Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, Nos | | 2 | 2 |
| | Gastrointestinal Stromal Sarcoma | | 1 | 1 |
| | Malignant Melanoma, Nos | | 1 | 1 |
| C22 Liver & intrahepatic bile ducts | Hepatocellular Carcinoma, Nos | 36 | 66 | 102 |
| | Cholangiocarcinoma | 9 | 10 | 19 |
| | Hepatoblastoma | 4 | 7 | 11 |
| | Adenocarcinoma, Nos | | 1 | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Yolk Sac Tumor | 1 | | 1 |
| C23-C24 Gallbladder & | Adenocarcinoma, Nos | 31 | 33 | 64 |

| | | | | |
|--|---|----|----|----|
| other and unspecified parts of biliary tract | Cholangiocarcinoma | 6 | 4 | 10 |
| | Adenocarcinoma, Intestinal Type | 2 | 5 | 7 |
| | Neoplasm, Malignant | 4 | 3 | 7 |
| | Carcinoma, Nos | 1 | 2 | 3 |
| | Signet Ring Cell Carcinoma | 1 | 2 | 3 |
| | Adenocarcinoma In Villous Adenoma | 2 | | 2 |
| | Adenosquamous Carcinoma | | 2 | 2 |
| | Adenocarcinoma In Tubulovillous Adenoma | | 1 | 1 |
| | Klatskin Tumor | 1 | | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Neuroendocrine Carcinoma, Nos | | 1 | 1 |
| | Squamous Cell Carcinoma, Nos | | 1 | 1 |
| C25 Pancreas | Adenocarcinoma, Nos | 19 | 35 | 54 |
| | Neuroendocrine Carcinoma, Nos | 7 | 10 | 17 |
| | Neoplasm, Malignant | 4 | 1 | 5 |
| | Carcinoma, Nos | 1 | 3 | 4 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Mucinous Adenocarcinoma | | 1 | 1 |
| | Solid Pseudopapillary Carcinoma | 1 | | 1 |
| C30-C31 Nasal cavity, middle ear and accessory sinuses | Squamous Cell Carcinoma, Nos | 6 | 3 | 9 |
| | Adenoid Cystic Carcinoma | 3 | 4 | 7 |
| | Carcinoma, Nos | 1 | 1 | 2 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 1 | 1 | 2 |
| | Carcinoma, Undifferentiated, Nos | | 1 | 1 |
| | Ewing Sarcoma | 1 | | 1 |
| | Malignant Melanoma, Nos | 1 | | 1 |
| | Malignant Myoepithelioma | | 1 | 1 |
| | Nk/T-Cell Lymphoma, Nasal And Nasal-Type | | 1 | 1 |
| | Small Cell Carcinoma, Nos | | 1 | 1 |
| | Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, Nos | | 1 | 1 |
| Squamous Cell Carcinoma, Spindle Cell | | 1 | 1 | |
| C32 Larynx | Squamous Cell Carcinoma, Nos | 6 | 41 | 47 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 1 | 5 | 6 |
| | Adenoid Cystic Carcinoma | 2 | | 2 |
| | Carcinoma In Situ, Nos | | 2 | 2 |

| | | | | |
|---|--|----|----|----|
| | Squamous Cell Carcinoma In Situ, Nos | 1 | 1 | 2 |
| | Basaloid Squamous Cell Carcinoma | | 1 | 1 |
| | Chondrosarcoma, Nos | | 1 | 1 |
| C33-C34 Trachea, bronchus and lung | Adenocarcinoma, Nos | 21 | 30 | 51 |
| | Squamous Cell Carcinoma, Nos | 2 | 48 | 50 |
| | Small Cell Carcinoma, Nos | 2 | 29 | 31 |
| | Acinar Cell Carcinoma | 8 | 2 | 10 |
| | Neoplasm, Malignant | 5 | 3 | 8 |
| | Neuroendocrine Carcinoma, Nos | 2 | 5 | 7 |
| | Non-Small Cell Carcinoma | | 3 | 3 |
| | Carcinoma, Nos | 2 | | 2 |
| | Ewing Sarcoma | 1 | 1 | 2 |
| | Adenocarcinoma With Mixed Subtypes | | 1 | 1 |
| | Combined Small Cell Carcinoma | 1 | | 1 |
| | Fetal Adenocarcinoma | | 1 | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Mucinous Adenocarcinoma | 1 | | 1 |
| | Mucoepidermoid Carcinoma | | 1 | 1 |
| Squamous Cell Carcinoma, Keratinizing, Nos | | 1 | 1 | |
| C37-C38 Thymus, heart, mediastinum & pleura | Malignant Lymphoma, Large B-Cell Diffuse Nos | 1 | 6 | 7 |
| | Neuroendocrine Carcinoma, Nos | | 3 | 3 |
| | Thymoma, Type B2, Malignant | | 3 | 3 |
| | Yolk Sac Tumor | 1 | 2 | 3 |
| | Germ Cell Tumor, Nonseminomatous | | 2 | 2 |
| | Mesothelioma, Malignant | 2 | | 2 |
| | Follicular Lymphoma, Grade 2 | 1 | | 1 |
| | Hodgkin Lymphoma, Nos | 1 | | 1 |
| | Mixed Germ Cell Tumor | | 1 | 1 |
| | Neoplasm, Malignant | 1 | | 1 |
| | Small Cell Carcinoma, Nos | 1 | | 1 |
| | Thymoma, Type Ab, Malignant | | 1 | 1 |
| | Thymoma, Type B2, Nos | | 1 | 1 |
| | Thymoma, Type B3, Malignant | | 1 | 1 |
| C40-41 Bones, Joints & Articular Cartilage | Osteosarcoma, Nos | 19 | 34 | 53 |
| | Ewing Sarcoma | 17 | 28 | 45 |

| | | | | |
|--|--|----|----|-----|
| | Chondrosarcoma, Nos | 5 | 6 | 11 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 2 | 6 | 8 |
| | Chondroblastic Osteosarcoma | | 5 | 5 |
| | Spindle Cell Sarcoma | 1 | 1 | 2 |
| | Burkitt Lymphoma, Nos | | 1 | 1 |
| | Dedifferentiated Chondrosarcoma | | 1 | 1 |
| | Hodgkin Lymphoma, Nos | 1 | | 1 |
| | Langerhans Cell Histiocytosis, Multifocal | | 1 | 1 |
| | Langerhans Cell Histiocytosis, Nos | | 1 | 1 |
| | Plasmacytoma, Nos | | 1 | 1 |
| | Sarcoma, Nos | | 1 | 1 |
| | Telangiectatic Osteosarcoma | | 1 | 1 |
| C42 Hematopoietic and reticuloendothelial system | Precursor B-Cell Lymphoblastic Leukemia | 46 | 73 | 119 |
| | B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 27 | 61 | 88 |
| | Multiple Myeloma | 8 | 11 | 19 |
| | Acute Myeloid Leukemia, Nos | 5 | 9 | 14 |
| | Precursor T-Cell Lymphoblastic Leukemia | 2 | 8 | 10 |
| | Chronic Myeloid Leukemia, Nos | 3 | 5 | 8 |
| | Myelodysplastic Syndrome, Nos | 3 | 4 | 7 |
| | Chronic Myelogenous Leukemia, Bcr/Abl Positive | 3 | 3 | 6 |
| | Essential Thrombocythemia | 2 | 3 | 5 |
| | Acute Monocytic Leukemia | | 1 | 1 |
| | Acute Myeloid Leukemia Without Maturation Fab M1 | | 1 | 1 |
| | Acute Myeloid Leukemia, Minimal Differentiation Fab M0 | | 1 | 1 |
| | Acute Myelomonocytic Leukemia Fab M4 | | 1 | 1 |
| | Acute Promyelocytic Leukemia, | | 1 | 1 |
| | Chronic Myelomonocytic Leukemia, Nos | 1 | | 1 |
| | Chronic Myeloproliferative Disease, Nos | | 1 | 1 |
| | Hairy Cell Leukemia | | 1 | 1 |
| | Langerhans Cell Histiocytosis, Nos | 1 | | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Mixed Phenotype Acute Leukemia, B/Myeloid, Nos | 1 | | 1 |
| Myelodysplastic Syndrome With 5q Deletion (5q-) Syndrome | | 1 | 1 | |
| Precursor Cell Lymphoblastic Leukemia, Nos | | 1 | 1 | |

| | | | | |
|---|--|----|----|----|
| | Refractory Cytopenia With Multilineage Dysplasia | 1 | | 1 |
| C44 Skin | Basal Cell Carcinoma, Nodular | 45 | 44 | 89 |
| | Squamous Cell Carcinoma, Nos | 19 | 62 | 81 |
| | Malignant Melanoma, Nos | 12 | 17 | 29 |
| | Basal Cell Carcinoma, Nos | 9 | 17 | 26 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 8 | 5 | 13 |
| | Dermatofibrosarcoma, Nos | 1 | 6 | 7 |
| | Sebaceous Adenocarcinoma | 3 | 1 | 4 |
| | Adenoid basal Cell Carcinoma, Nos | | 3 | 3 |
| | Squamous Cell Carcinoma In Situ, Nos | 1 | 2 | 3 |
| | Basaloid Squamous Cell Carcinoma | 1 | 1 | 2 |
| | Nodular Hidradenoma, Malignant | 1 | 1 | 2 |
| | Adenosquamous Carcinoma | | 1 | 1 |
| | Basosquamous Carcinoma | 1 | | 1 |
| | Carcinoma In Situ, Nos | | 1 | 1 |
| | Carcinoma, Nos | 1 | | 1 |
| | Cutaneous T-Cell Lymphoma, Nos | 1 | | 1 |
| | Langerhans Cell Histiocytosis, Nos | | 1 | 1 |
| | Mycosis Fungoides | 1 | | 1 |
| | Myeloid Sarcoma | 1 | | 1 |
| | Nodular Melanoma | | 1 | 1 |
| Skin Appendage Carcinoma | | 1 | 1 | |
| | Squamous Cell Carcinoma, Spindle Cell | 1 | | 1 |
| C47 Periph. nerves & auto-immune N.S. | Malignant Peripheral Nerve Sheath Tumor | 2 | 1 | 3 |
| | Angiomyosarcoma | | 1 | 1 |
| C48 Retroperitoneum & Peritoneum | Dysgerminoma | 2 | | 2 |
| | Embryonal Rhabdomyosarcoma, Nos | 1 | | 1 |
| | Liposarcoma, Nos | | 1 | 1 |
| C49 Connective, subcutaneous & other soft tissues | Synovial Sarcoma, Nos | 11 | 16 | 27 |
| | Spindle Cell Sarcoma | 13 | 8 | 21 |
| | Undifferentiated Sarcoma | 7 | 13 | 20 |
| | Leiomyosarcoma Nos | 4 | 4 | 8 |
| | Embryonal Rhabdomyosarcoma, Nos | 3 | 4 | 7 |
| | Ewing Sarcoma | 2 | 5 | 7 |
| | Fibromyxosarcoma | 2 | 2 | 4 |

| | | | | |
|------------|---|------|---|------|
| | Liposarcoma, Well Differentiated | | 4 | 4 |
| | Dedifferentiated Liposarcoma | 3 | | 3 |
| | Epithelioid Sarcoma | 2 | 1 | 3 |
| | Myxoid Liposarcoma | 2 | 1 | 3 |
| | Pleomorphic Liposarcoma | 1 | 2 | 3 |
| | Synovial Sarcoma, Biphasic | 2 | 1 | 3 |
| | Clear Cell Sarcoma, Nos | 1 | 1 | 2 |
| | Giant Cell Sarcoma | | 2 | 2 |
| | Rhabdomyosarcoma, Nos | 1 | 1 | 2 |
| | Sarcoma, Nos | 1 | 1 | 2 |
| | Spindle Cell Rhabdomyosarcoma | | 2 | 2 |
| | Synovial Sarcoma, Spindle Cell | | 2 | 2 |
| | Alveolar Rhabdomyosarcoma | 1 | | 1 |
| | Angiomyosarcoma | | 1 | 1 |
| | Dermatofibrosarcoma, Nos | | 1 | 1 |
| | Epithelioma, Malignant | 1 | | 1 |
| | Kaposi Sarcoma | | 1 | 1 |
| | Liposarcoma, Nos | | 1 | 1 |
| | Malignant Fibrous Histiocytoma | | 1 | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Pleomorphic Rhabdomyosarcoma, Adult Type | | 1 | 1 |
| C50 Breast | Infiltrating Duct Carcinoma, Nos | 1082 | 8 | 1090 |
| | Lobular Carcinoma, Nos | 64 | | 64 |
| | Infiltrating Duct Mixed With Other Types Of Carcinoma | 23 | | 23 |
| | Ductal Carcinoma In Situ, Solid Type | 14 | | 14 |
| | Carcinoma, Nos | 12 | | 12 |
| | Metaplastic Carcinoma, Nos | 11 | | 11 |
| | Infiltrating Duct And Lobular Carcinoma | 8 | | 8 |
| | Inflammatory Carcinoma | 6 | | 6 |
| | Mucinous Adenocarcinoma | 6 | | 6 |
| | Paget Disease And Infiltrating Duct Carcinoma Of Breast | 5 | 1 | 6 |
| | Comedocarcinoma, Noninfiltrating | 5 | | 5 |
| | Neoplasm, Malignant | 5 | | 5 |
| | Papillary Carcinoma, Nos | 5 | | 5 |
| | Phyllodes Tumor, Malignant | 4 | | 4 |

| | | | | |
|---------------------------------------|---|----|---|----|
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 3 | | 3 |
| | Intraductal Micropapillary Carcinoma | 2 | | 2 |
| | Lobular Carcinoma In Situ, Nos | 2 | | 2 |
| | Paget Disease And Intraductal Carcinoma Of Breast | 2 | | 2 |
| | Paget Disease, Mammary | 2 | | 2 |
| | Apocrine Adenocarcinoma | 1 | | 1 |
| | Intraductal Carcinoma, Noninfiltrating, Nos | 1 | | 1 |
| | Papillary Carcinoma In Situ | 1 | | 1 |
| C51-C52 Vulva & Vagina | Squamous Cell Carcinoma, Keratinizing, Nos | 5 | | 5 |
| | Clear Cell Adenocarcinoma, Nos | 4 | | 4 |
| | Squamous Cell Carcinoma, Nos | 4 | | 4 |
| | Adenocarcinoma, Nos | 2 | | 2 |
| | Epithelioid Sarcoma | 1 | | 1 |
| | Malignant Melanoma, Nos | 1 | | 1 |
| | Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, Nos | 1 | | 1 |
| C53 Cervix uteri | Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, Nos | 42 | | 42 |
| | Squamous Cell Carcinoma, Nos | 42 | | 42 |
| | Squamous Cell Carcinoma, Keratinizing, Nos | 39 | | 39 |
| | Adenocarcinoma, Nos | 10 | | 10 |
| | Carcinoma, Nos | 6 | | 6 |
| | Adenocarcinoma, Endocervical Type | 4 | | 4 |
| | Endometrioid Adenocarcinoma, Nos | 4 | | 4 |
| | Clear Cell Adenocarcinoma, Nos | 3 | | 3 |
| | Adenosquamous Carcinoma | 2 | | 2 |
| | Carcinoma In Situ, Nos | 2 | | 2 |
| | Squamous Cell Carcinoma In Situ, Nos | 2 | | 2 |
| | Carcinoma, Undifferentiated, Nos | 1 | | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 1 | | 1 |
| | Mucinous Adenocarcinoma, Endocervical Type | 1 | | 1 |
| | Neoplasm, Malignant | 1 | | 1 |
| | Neuroendocrine Carcinoma, Nos | 1 | | 1 |
| | Serous Cystadenocarcinoma, Nos | 1 | | 1 |
| Squamous Cell Carcinoma, Spindle Cell | 1 | | 1 | |
| C54 Corpus uteri | Endometrioid Adenocarcinoma, Nos | 64 | | 64 |
| | Serous Cystadenocarcinoma, Nos | 16 | | 16 |

| | | | | |
|------------|--|----|--|----|
| | Carcinosarcoma, Nos | 6 | | 6 |
| | Endometrial Stromal Sarcoma, Nos | 4 | | 4 |
| | Carcinoma, Nos | 2 | | 2 |
| | Adenocarcinoma, Nos | 1 | | 1 |
| | Adenosarcoma | 1 | | 1 |
| | Choriocarcinoma, Nos | 1 | | 1 |
| | Endometrial Stromal Sarcoma, Low Grade | 1 | | 1 |
| | Leiomyosarcoma Nos | 1 | | 1 |
| | Mixed Cell Adenocarcinoma | 1 | | 1 |
| | Mullerian Mixed Tumor | 1 | | 1 |
| | Papillary Serous Cystadenocarcinoma | 1 | | 1 |
| | Squamous Cell Carcinoma, Nos | 1 | | 1 |
| | Stromal Sarcoma, Nos | 1 | | 1 |
| C55 Uterus | Choriocarcinoma, Nos | 3 | | 3 |
| | Leiomyosarcoma Nos | 2 | | 2 |
| | Dysgerminoma | 1 | | 1 |
| | Serous Cystadenocarcinoma, Nos | 1 | | 1 |
| | Spindle Cell Sarcoma | 1 | | 1 |
| | Stromal Sarcoma, Nos | 1 | | 1 |
| C56 Ovary | Serous Cystadenocarcinoma, Nos | 35 | | 35 |
| | Teratoma, Malignant, Nos | 11 | | 11 |
| | Dysgerminoma | 10 | | 10 |
| | Mucinous Adenocarcinoma | 9 | | 9 |
| | Endometrioid Adenocarcinoma, Nos | 8 | | 8 |
| | Mixed Germ Cell Tumor | 8 | | 8 |
| | Yolk Sac Tumor | 8 | | 8 |
| | Clear Cell Adenocarcinoma, Nos | 7 | | 7 |
| | Carcinoma, Nos | 3 | | 3 |
| | Neoplasm, Malignant | 3 | | 3 |
| | Papillary Serous Cystadenocarcinoma | 3 | | 3 |
| | Granulosa Cell Tumor, Malignant | 2 | | 2 |
| | Adenocarcinoma, Nos | 1 | | 1 |
| | Carcinosarcoma, Nos | 1 | | 1 |
| | Choriocarcinoma, Nos | 1 | | 1 |
| | Germ Cell Tumor, Nonseminomatous | 1 | | 1 |

| | | | | |
|---|--|----|-----|-----|
| | Granular Cell Tumor, Malignant | 1 | | 1 |
| | Mixed Cell Adenocarcinoma | 1 | | 1 |
| | Mucinous Cystadenocarcinoma, Nos | 1 | | 1 |
| | Squamous Cell Carcinoma, Nos | 1 | | 1 |
| C57 Other and unspecified female genital organs | Carcinosarcoma, Nos | 1 | | 1 |
| | Clear Cell Adenocarcinoma, Nos | 1 | | 1 |
| | Serous Cystadenocarcinoma, Nos | 1 | | 1 |
| C58 Placenta | Choriocarcinoma, Nos | 1 | | 1 |
| C60 Penis | Squamous Cell Carcinoma, Keratinizing, Nos | | 1 | 1 |
| | Squamous Cell Carcinoma, Nos | | 1 | 1 |
| C61 Prostate | Adenocarcinoma, Nos | | 253 | 253 |
| | Neoplasm, Malignant | | 7 | 7 |
| | Carcinoma, Nos | | 2 | 2 |
| | Neuroendocrine Carcinoma, Nos | | 1 | 1 |
| | Transitional Cell Carcinoma, Nos | | 1 | 1 |
| C62-63 Testis & other male genital organs | Mixed Germ Cell Tumor | | 72 | 72 |
| | Seminoma, Nos | | 65 | 65 |
| | Yolk Sac Tumor | | 17 | 17 |
| | Embryonal Carcinoma, Nos | | 16 | 16 |
| | Teratoma, Malignant, Nos | | 6 | 6 |
| | Neoplasm, Malignant | | 5 | 5 |
| | Germ Cell Tumor, Nonseminomatous | | 2 | 2 |
| | Germinoma | | 2 | 2 |
| | Squamous Cell Carcinoma, Nos | | 2 | 2 |
| | Burkitt Lymphoma, Nos | | 1 | 1 |
| | Carcinoma, Nos | | 1 | 1 |
| | Dedifferentiated Liposarcoma | | 1 | 1 |
| | Embryonal Rhabdomyosarcoma, Nos | | 1 | 1 |
| | Granulosa Cell Tumor, Malignant | | 1 | 1 |
| | Leiomyosarcoma Nos | | 1 | 1 |
| | Neuroendocrine Carcinoma, Nos | | 1 | 1 |
| | Spermatocytic Seminoma | | 1 | 1 |
| Stromal Sarcoma, Nos | | 1 | 1 | |
| C64-C66 Kidney, renal pelvis and ureter | Renal Cell Carcinoma, Nos | 47 | 70 | 117 |
| | Nephroblastoma, Nos | 12 | 15 | 27 |

| | | | | |
|----------------------------|--|----|----|----|
| | Renal Cell Carcinoma, Chromophobe Type | 4 | 9 | 13 |
| | Neoplasm, Malignant | 1 | 3 | 4 |
| | Clear Cell Adenocarcinoma, Nos | 1 | 2 | 3 |
| | Papillary Adenocarcinoma, Nos | 1 | 2 | 3 |
| | Carcinoma, Nos | | 2 | 2 |
| | Renal Cell Carcinoma, Sarcomatoid | | 2 | 2 |
| | Transitional Cell Carcinoma, Nos | | 2 | 2 |
| | Clear Cell Sarcoma Of Kidney | | 1 | 1 |
| | Ewing Sarcoma | | 1 | 1 |
| | Papillary Transitional Cell Carcinoma | | 1 | 1 |
| C67 Bladder | Papillary Transitional Cell Carcinoma | 9 | 48 | 57 |
| | Transitional Cell Carcinoma, Nos | 4 | 24 | 28 |
| | Squamous Cell Carcinoma, Nos | 1 | 1 | 2 |
| | Neuroendocrine Carcinoma, Nos | | 1 | 1 |
| | Transitional Cell Carcinoma, Spindle Cell | | 1 | 1 |
| C69 Eye and Adnexa | Retinoblastoma, Nos | 16 | 22 | 38 |
| | Embryonal Rhabdomyosarcoma, Nos | 2 | | 2 |
| | Retinoblastoma, Differentiated | 1 | 1 | 2 |
| | Adenoid Cystic Carcinoma | 1 | | 1 |
| | Carcinoma, Nos | | 1 | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Retinoblastoma, Undifferentiated | 1 | | 1 |
| | Spindle Cell Melanoma, Nos | 1 | | 1 |
| | Squamous Cell Carcinoma, Nos | 1 | | 1 |
| C70-C71 Meninges and brain | Glioma, Malignant | 26 | 53 | 79 |
| | Astrocytoma, Nos | 24 | 36 | 60 |
| | Glioblastoma, Nos | 13 | 37 | 50 |
| | Oligodendroglioma, Nos | 8 | 6 | 14 |
| | Meningioma, Nos | 6 | 5 | 11 |
| | Astrocytoma, Anaplastic | 5 | 2 | 7 |
| | Neoplasm, Malignant | | 4 | 4 |
| | Oligodendroglioma, Anaplastic | 1 | 3 | 4 |
| | Ependymoma, Nos | | 3 | 3 |
| | Hemangioblastoma | 1 | 2 | 3 |
| | Medulloblastoma, Nos | 3 | | 3 |

| | | | | |
|--|---|----|----|-----|
| | Neoplasm, Uncertain Whether Benign Or Malignant | 2 | 1 | 3 |
| | Central Neurocytoma | | 2 | 2 |
| | Hemangiopericytoma, Malignant | 1 | 1 | 2 |
| | Meningioma, Malignant | 2 | | 2 |
| | Pilocytic Astrocytoma | | 2 | 2 |
| | Gemistocytic Astrocytoma | | 1 | 1 |
| | Gliosarcoma | | 1 | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 1 | | 1 |
| | Malignant Lymphoma, Non-Hodgkin, Nos | | 1 | 1 |
| | Neurilemoma, Nos | | 1 | 1 |
| | Pilomyxoid Astrocytoma | | 1 | 1 |
| C72 Spinal cord, cranial nerves & other parts of CNS | Ependymoma, Nos | 3 | 7 | 10 |
| | Neurilemoma, Nos | 1 | 4 | 5 |
| | Myxopapillary Ependymoma | | 3 | 3 |
| | Glioma, Malignant | 1 | 1 | 2 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 1 | 1 | 2 |
| | Neoplasm, Malignant | 2 | | 2 |
| | Burkitt Lymphoma, Nos | 1 | | 1 |
| | Plasmacytoma, Nos | 1 | | 1 |
| C73 Thyroid | Papillary Carcinoma, Nos | 84 | 43 | 127 |
| | Follicular Adenocarcinoma, Nos | 8 | 3 | 11 |
| | Medullary Carcinoma, Nos | 10 | 1 | 11 |
| | Oxyphilic Adenocarcinoma | 2 | 3 | 5 |
| | Carcinoma, Anaplastic, Nos | | 2 | 2 |
| | Carcinoma, Nos | 2 | | 2 |
| | Papillary Microcarcinoma | 2 | | 2 |
| | Adenocarcinoma, Nos | | 1 | 1 |
| | Follicular Carcinoma, Minimally Invasive | 1 | | 1 |
| | Micropapillary Carcinoma,Nos | 1 | | 1 |
| | Neoplasm, Malignant | 1 | | 1 |
| | Papillary Carcinoma, Encapsulated | 1 | | 1 |
| Papillary Carcinoma, Oxyphilic Cell | | 1 | 1 | |
| C74 Adrenal gland | Adrenal Cortical Carcinoma | 4 | 2 | 6 |
| | Pheochromocytoma, Malignant | 1 | | 1 |
| C75 Other endocrine glands | Pituitary Adenoma, Nos | 25 | 23 | 48 |

| | | | | |
|---|---|----|-----|-----|
| & related structures | Prolactinoma | 2 | 1 | 3 |
| | Craniopharyngioma | | 1 | 1 |
| | Pineoblastoma | 1 | | 1 |
| C76 Other & ill-defined sites | Malignant Lymphoma, Large B-Cell Diffuse Nos | 3 | 1 | 4 |
| | Burkitt Lymphoma, Nos | 1 | 2 | 3 |
| | Gastrointestinal Stromal Sarcoma | 1 | 2 | 3 |
| | Yolk Sac Tumor | 1 | 2 | 3 |
| | Carcinoma, Nos | | 2 | 2 |
| | Seminoma, Nos | | 2 | 2 |
| | Adenoid Cystic Carcinoma | | 1 | 1 |
| | Dysgerminoma | 1 | | 1 |
| | Embryonal Carcinoma, Nos | | 1 | 1 |
| | Malignant Tumor, Clear Cell Type | 1 | | 1 |
| | Mixed Germ Cell Tumor | 1 | | 1 |
| | Neoplasm, Malignant | 1 | | 1 |
| | Small Cell Carcinoma, Nos | 1 | | 1 |
| C77 Lymph nodes, (NHL,HL) | Hodgkin Lymphoma, Mixed Cellularity, Nos | 43 | 150 | 193 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | 43 | 106 | 149 |
| | Hodgkin Lymphoma, Nodular Sclerosis, Nos | 39 | 54 | 93 |
| | Burkitt Lymphoma, Nos | 5 | 30 | 35 |
| | Hodgkin Lymphoma, Nos | 7 | 20 | 27 |
| | Hodgkin Lymphoma, Nodular Lymphocyte Predominance | 4 | 21 | 25 |
| | Hodgkin Lymphoma, Lymphocyte-Rich | | 7 | 7 |
| | Precursor T-Cell Lymphoblastic Lymphoma | 2 | 5 | 7 |
| | Follicular Lymphoma, Grade 3 | 2 | 3 | 5 |
| | Malignant Lymphoma, Non-Hodgkin, Nos | 3 | 2 | 5 |
| | Marginal Zone B-Cell Lymphoma, Nos | 3 | 2 | 5 |
| | Anaplastic Large Cell Lymphoma, T Cell And Null Cell Type | 1 | 3 | 4 |
| | T-Cell/Histiocyte Rich Large B-Cell Lymphoma | 1 | 3 | 4 |
| | Alk Positive Large B-Cell Lymphoma | 1 | 2 | 3 |
| | Composite Hodgkin And Non-Hodgkin Lymphoma | 3 | | 3 |
| | Follicular Lymphoma, Grade 1 | 1 | 2 | 3 |
| | Follicular Lymphoma, Grade 2 | 1 | 2 | 3 |
| | Mantle Cell Lymphoma | | 3 | 3 |
| Precursor B-Cell Lymphoblastic Lymphoma | 3 | | 3 | |

| | | | | |
|--------------------------|--|-------------|-------------|-------------|
| | Mature T-Cell Lymphoma, Nos | | 2 | 2 |
| | Angioimmunoblastic T-Cell Lymphoma | | 1 | 1 |
| | B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | | 1 |
| | Langerhans Cell Histiocytosis, Nos | 1 | | 1 |
| | Malignant Lymphoma, Small B Lymphocytic, Nos | | 1 | 1 |
| | Precursor Cell Lymphoblastic Lymphoma, Nos | | 1 | 1 |
| C80 Unknown primary site | Neoplasm, Malignant | 9 | 5 | 14 |
| | Adenocarcinoma, Nos | 5 | 3 | 8 |
| | Carcinoma, Nos | 5 | 1 | 6 |
| | Yolk Sac Tumor | | 2 | 2 |
| | Embryonal Carcinoma, Nos | | 1 | 1 |
| | Germinoma | 1 | | 1 |
| | Malignant Lymphoma, Large B-Cell Diffuse Nos | | 1 | 1 |
| | Malignant Lymphoma, Non-Hodgkin, Nos | | 1 | 1 |
| | Marginal Zone B-Cell Lymphoma, Nos | | 1 | 1 |
| | Squamous Cell Carcinoma, Nos | 1 | | 1 |
| Grand Total | | 3323 | 3123 | 6446 |

"NOS" is an abbreviation for Not Otherwise Specified